Findings

What do systematic reviews say?

4,730 questions · 18,059 findings · 1,282 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4,360 · 24.1%GRADE not reported 2,529 · 14%Very low 4,641 · 25.7%Low 4,007 · 22.2%Moderate 2,057 · 11.4%High 465 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Cyclosporin vs intravenous immunoglobulin (IVIG)

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs no corticosteroid use

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs no IVIG

Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
RR 0.33 [0.04, 2.91]
1 study · 36 participants
Very low

IVIg vs no IVIG

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Very low

IVIg vs no IVIG

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs no IVIG

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Very low

Metformin vs placebo or no treatment

Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

H2 receptor antagonists vs placebo

Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

H2 receptor antagonists vs placebo

Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Very low

H2 receptor antagonists vs placebo

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.07 [0.72, 1.57]
2 studies · 189 participants
Low

H2 receptor antagonists vs placebo

Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

H2 receptor antagonists vs placebo

Nausea · people with schizophrenia with antipsychotic‐induced weight gain

H2 antagonists showed no clear difference in reports of nausea compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.13 [0.34, 3.68]
1 study · 175 participants
Low

Monoamine modulators vs placebo

Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Monoamine modulators vs placebo

Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 103 participants
Low

Monoamine modulators vs placebo

Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported